Ask AI

Ready, Set, Complement! Novel C5 Inhibitors in Generalized Myasthenia Gravis

Explore the evolving treatment landscape in myasthenia gravis through a multimodal educational program focused on C5 inhibition, emerging complement-directed therapies, and individualized care. This program features an on-demand webcast including a patient interview, expert ClinicalThought commentaries, and a downloadable slideset. These activities provide practical guidance on efficacy, safety, administration, patient selection, and long-term treatment considerations for new options in myasthenia gravis patient care.

Share

Program Content

Events

Activities

Complement Inhibition Rationale Commentary
Complement Inhibition in Generalized Myasthenia Gravis: Rationale, Mechanism of Action, and Clinical Trial Data
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 10, 2026

Expires: September 09, 2027

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by an educational grant from AstraZeneca.

AstraZeneca